Atyr Pharma Inc Stock Price, News & Analysis

aTyr Pharma, a clinical stage biotech company developing medicines from its tRNA synthetase platform, has announced its participation in the 17th Annual LD Micro Main Event. The event is scheduled for October 28-30, 2024, in Los Angeles, CA.

Dr. Sanjay S. Shukla, President and CEO of aTyr Pharma, will present a corporate overview on Tuesday, October 29, 2024, at 9:00am PDT at the Luxe Sunset Boulevard Hotel. The three-day event will feature approximately 150 companies presenting in half-hour increments and attending private meetings with investors.

Interested parties can view aTyr's presentation online and request meetings with management by contacting registration@ldmicro.com. This event provides an opportunity for aTyr Pharma to showcase its progress in developing first-in-class medicines to potential investors and industry professionals.

aTyr Pharma announced that its lead therapeutic candidate, efzofitimod, will be featured in the Best of CHEST Journals session at the CHEST 2024 Annual Meeting in Boston, MA. The presentation, titled 'Efzofitimod for the Treatment of Pulmonary Sarcoidosis,' will be given by Dr. Daniel A. Culver on October 8, 2024. It will review data from a Phase 1b/2a study showing efzofitimod's ability to reduce steroid use while controlling symptoms in pulmonary sarcoidosis patients.

Efzofitimod is currently being investigated in the global Phase 3 EFZO-FIT™ study with 268 pulmonary sarcoidosis patients. Topline data is expected in Q3 2025. The drug is a first-in-class biologic immunomodulator designed to treat interstitial lung disease by modulating activated myeloid cells to resolve inflammation without immune suppression.

aTyr Pharma (Nasdaq: ATYR) announced the publication of a post hoc analysis of their Phase 1b/2a clinical trial for efzofitimod in pulmonary sarcoidosis patients in the European Respiratory Journal. The analysis showed a statistically significant difference in time-to-first-relapse for corticosteroid use between therapeutic (3.0 and 5.0 mg/kg efzofitimod) and subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups.

Key findings include:

• 54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compared to only 7.7% in the therapeutic group
• Median time-to-first-relapse in the subtherapeutic group was 126 days, while only one of 17 patients in the therapeutic group relapsed by the end of the study (p=0.017)

Efzofitimod is currently being investigated in the global pivotal Phase 3 EFZO-FIT™ study in 268 pulmonary sarcoidosis patients.

aTyr Pharma, a clinical stage biotechnology company, announced its participation in three investor conferences in September 2024. These include the Wells Fargo Healthcare Conference on September 5 in Everett, MA (1x1 investor meetings), the H.C. Wainwright 26th Annual Global Investment Conference on September 11 in New York, NY (corporate presentation at 10:30am EDT), and the Cantor Fitzgerald Global Healthcare Conference on September 18 in New York, NY (corporate presentation at 1:55pm EDT).

Webcasts of the H.C. Wainwright and Cantor Fitzgerald presentations will be available on aTyr's website for at least 90 days. The company's management will also be available for one-on-one meetings with registered conference attendees. aTyr focuses on developing therapies for fibrosis and inflammation using tRNA synthetase biology, with their lead candidate efzofitimod targeting interstitial lung disease.

aTyr Pharma (Nasdaq: ATYR) announced Q2 2024 results and provided a corporate update. Key highlights include:

1. Completed enrollment in the Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis, with 268 patients. Topline data expected in Q3 2025.

2. Continued enrollment in the Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD. Interim data expected in Q2 2025.

3. Presented efzofitimod's mechanism of action at the ATS 2024 International Conference.

4. Entered a research agreement with Stanford Medicine to explore anti-NRP2 antibodies in glioblastoma multiforme.

5. Appointed Jayant Aphale, Ph.D., as VP of Technical Operations.

6. Financial position: $81.4 million in cash and investments as of June 30, 2024. R&D expenses were $14.0 million, and G&A expenses were $3.3 million for Q2 2024.

aTyr Pharma (Nasdaq: ATYR) has appointed Jayant Aphale, PhD, as Vice President of Technical Operations. Dr. Aphale will oversee manufacturing activities and implement strategies for commercial manufacturing, supply chain management, and process development. This appointment comes as aTyr prepares for the potential commercialization of its lead candidate, efzofitimod, for pulmonary sarcoidosis.

Key points:

• Pivotal Phase 3 data for efzofitimod expected in Q3 2025
• Commercial manufacturing process validation to begin later this year
• Dr. Aphale brings over 30 years of pharmaceutical industry experience
• He previously worked at Sarepta Therapeutics, GSK Vaccines, and other major companies
• Dr. Aphale received a stock option grant for 150,000 shares as part of his employment package

aTyr Pharma (Nasdaq: ATYR) has entered a research agreement with Stanford Medicine to explore the role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common primary brain cancer. The study, led by Dr. Michael Lim, aims to investigate the potential of aTyr's novel function blocking antibodies against NRP2 in combination with chemotherapy to reverse immune evasion in GBM. If successful, researchers plan to evaluate NRP2 antibodies with other immunomodulating agents to address myeloid and T cell immunosuppression in GBM treatment.

This collaboration aligns with aTyr's belief that NRP2 plays a important role in immune cross talk in various cancers. The research could enhance understanding of NRP2's role in mediating immune suppression in aggressive cancers like GBM, where there is a high unmet medical need. GBM's current standard of care includes surgery, radiation, and chemotherapy, but the rate of recurrence remains high, emphasizing the need for new treatments to manage recurrence.

aTyr Pharma (Nasdaq: ATYR) has completed enrollment in its global pivotal Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis. The study enrolled 268 patients across 85 centers in 9 countries, surpassing the target enrollment. This marks the largest interventional study ever conducted in pulmonary sarcoidosis. Topline data are expected in Q3 2025.

Efzofitimod is a first-in-class biologic immunomodulator designed to treat interstitial lung disease. It has received orphan drug designation in the U.S., E.U., and Japan for sarcoidosis and Fast Track designation in the U.S. for pulmonary sarcoidosis. The EFZO-FIT™ study aims to evaluate the efficacy and safety of efzofitimod, with steroid reduction as the primary endpoint.

aTyr Pharma announces a change in its Nasdaq stock ticker symbol from 'LIFE' to 'ATYR,' effective June 5, 2024, at market open.

The change reflects the company's focus on advancing its lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and preparing for potential commercialization.

No action is required by existing stockholders, and the company's common stock will continue to be listed on the Nasdaq Capital Market with the same CUSIP.

aTyr is a clinical stage biotech company developing first-in-class medicines based on its proprietary tRNA synthetase platform.